Kornimate/medical-research-clean huggingface dataset:
comparative effects of pendulum exercise and serratus punch exercises on rotator cuff pain in badminton players

Conditions: Sports Physical Therapy

Summary: this study will compare the effects of two exercise interventions, pendulum exercises and serratus punches, on rotator cuff pain and injury in badminton players. using a randomized clinical trial with participants from local clubs, the research will evaluate pain levels, range of motion, and shoulder function after a set period of regular, supervised exercises. the results aim to provide evidence-based insights for effective rehabilitation programs tailored to badminton athletes, supporting better recovery and injury prevention.

rotator cuff pain and disability is typical among badminton players because of the dull movements associated with the game. these wounds can prompt critical torment and practical limits, influencing the players' exhibition and prosperity. the focal point of this exploration project is to think about the impacts of two different activity mediations, pendulum activities and serratus punch works, on rotator sleeve agony and injury in badminton players. understanding the similar adequacy of these activities will contribute essential knowledge to improving designated restoration programs for badminton competitors, further developing their recuperation results and forestalling future wounds. this exploration will utilize a randomized clinical preliminary plan to research the similar impacts of pendulum activities and serratus punch practices on rotator sleeve agony and injury in badminton players. members will be selected from neighborhood badminton clubs, and consideration measures will include people with an analyzed or self-revealed history of rotator sleeve torment. the chosen members will be arbitrarily allotted to the pendulum or the serratus punch practice bunch. the mediation time frame will traverse a predefined span, during which members will routinely participate in their doled-out practice. result estimates will incorporate torment levels, scope of movement, and practical appraisals of the rotator sleeve. factual examinations will be directed to consider the viability of the two activity mediations and their effect on rotator sleeve agony and injury in badminton players. the consequences of this study are to illuminate proof-based restoration systems customized explicitly for the badminton populace, adding to the enhancement of player well-being and execution.

Eligibility criteria:
inclusion criteria: * badminton players aged 15 to 30 years. * individuals with self-reported rotator cuff pain or discomfort * clinically diagnosed rotator cuff pain or discomfort. * individuals with rotator cuff injury. exclusion criteria: * previous shoulder surgeries or fractures. * chronic shoulder conditions unrelated to rotator cuff issues. * inability to perform the prescribed exercises due to other musculoskeletal or medical conditions. * patients with shoulder dislocation. * patients with swelling on shoulder.

Keywords: rotator cuff injuries shoulder pain badminton injuries rehablitation
follow-up strategy for esophageal cancer patients

Conditions: Esophagus Cancer

Summary: the recurrence risk of patients with esophageal cancer was stratified by integrating different stages and pathological factors. the risk of recurrence was dynamically estimated for each group of patients, and the optimal follow-up strategy was developed based on the recurrence risk.

patients with histologically proven, esophageal cancer (ec) patients diagnosed between 2008 and 2018 were recruited. recursive partition analysis was applied to develop recurrence risk stratification for patients. the follow-up strategies of each stratification were developed based on monthly recurrence probability and validated by bootstrap validation and an external dataset. markov decision-analytic models were constructed to evaluate the cost-effectiveness of the follow-up strategies.

Eligibility criteria:
inclusion criteria: (1) patients aged between 18 and 80 years old; (2) pathological diagnosis as esophageal squamous cell carcinoma or adenocarcinoma; (3) patients underwent esophagectomy and received r0 resection. exclusion criteria: (1) patients with secondary primary tumor; (2) patients who died within 30 days after surgery or died of post-operation complications; (3) patients missing essential clinical information, such as operation record, pathological diagnosis, and follow-up data; (4) patients with radiologically or histologically confirmed distant metastasis; (5) patients previously underwent endoscopic mucosal resection or definitive radiochemotherapy as initial treatment.

Keywords: follow-up
evaluation of directional stimulation during the implantation of deep brain stimulation (dbs) leads

Conditions: Parkinson's Disease; Essential Tremor

Summary: the purpose of this study is to provide proof-of-concept that directional stimulation, in an intraoperative setting, is perceivable in a subject and is different from omnidirectional stimulation. the tests will be performed using a dedicated dbs lead connected to external neurostimulator.


Eligibility criteria:
inclusion criteria: * subject is indicated to undergo dbs for parkinson's disease or essential tremor according to criteria of the study site * for parkinson disease: * person is between 18 and 75 years of age * established diagnosis of idiopathic parkinson's disease with progression of symptoms for a minimum of 2 years. * person has a history of at least 30% improvement on the unified parkinson's disease rating scale with therapy in l-dopa (levodopa) * weak control of symptoms by dopaminergic therapy (off phenomenon, fluctuations on / off, dyskinesia on) * for essential tremor: * person is between 18 and 80 years of age * established diagnosis of essential tremor for a minimum of 2 years * functional disability due to tremor was not adequately controlled by medication for at least 3 months prior to implant. * person has given his/her written consent exclusion criteria: * person suffering from an active major psychiatric disorder * mattis dementia rating scale score \<130 or otherwise not capable of discernment * presence of major co-morbidity or medical condition that may affect participation to the study * presence of an electrical or electromagnetic implant (e.g., cochlear implant, pacemaker) * person with a previous surgery for the treatment of parkinson's disease or essential tremor * person with a previous brain ablation procedure * person who suffers from epilepsy * person who is pregnant: a pregnancy test will be performed in women of childbearing age * person with coagulopathies * abuse of drugs or alcohol
pioglitazone for the treatment of major depressive disorder comorbid with metabolic syndrome

Conditions: Depressive Disorder, Major; Metabolic Syndrome X

Summary: the goal of this study is to begin to test whether or not pioglitazone, an fda approved medication used to treat high blood sugar, may be safe and effective in treating major depressive disorder (mdd) in patients with comorbid metabolic syndrome (metsyn).


Eligibility criteria:
inclusion criteria: * be male or female between the ages of 18 and 70 * dsm-iv diagnosis of major depressive disorder * currently depressed as confirmed by the mini-plus at the screening visit * quick inventory of depressive symptomatology-self-report(qids-sr) score \> 11 at study baseline * meets criteria for the metabolic syndrome as defined by the ncep atp iii criteria exclusion criteria: * pregnancy or breast feeding * unstable or inadequately treated medical illness as judged by the investigator * severe personality disorder * serious suicidal risk as judged by the investigator or having a score \> 2 on item 18 of the inventory of depressive symptomatology-clinician rated (ids-cr) scale * known history of intolerance or hypersensitivity to pioglitazone * treatment with pioglitazone in the 3 months prior to randomization * currently taking an antidiabetic/glucose-lowering agent. antidiabetic agents that are prohibited include insulin, rosiglitazone, metformin, sitagliptin, sulfonylureas (e.g. glyburide, glipizide, glimepiride), non-sulfonylurea secretagogues (e.g. repaglinide, nateglinide), incretins (e.g. exenatide), and α-glucosidase inhibitors (e.g. acarbose, miglitol). * diagnosed with dementia * diagnosed with heart failure * transaminase elevation \>2.5 times the upper limit of normal * presence of renal impairment

Keywords: depressive disorder, major metabolic syndrome x pioglitazone
treatment of obsessive compulsive disorder in children

Conditions: Obsessive-Compulsive Disorder

Summary: this study will determine whether cognitive behavioral therapy delivered by either psychologists or psychiatrists can improve the effectiveness of serotonin reuptake inhibitor treatment in children with obsessive compulsive disorder.

the vast majority of children with obsessive compulsive disorder (ocd) are given serotonin reuptake inhibitor (sri) drugs as initial treatment. however, recommended doses of these medications leave many children with clinically significant residual symptoms. health care experts typically recommend augmenting sri treatment with cognitive behavioral therapy (cbt), yet this recommendation is seldom followed. this study will contrast two cbt augmentation strategies to continued medication management alone: cbt administered by a psychologist and instructional cbt (i-cbt)administered by a psychiatrist in the context of ongoing medication management. all patients in the trial will be eligible to receive a full course of cbt by study end. participants in this study will be randomly assigned to receive cbt, i-cbt or continued medication management. all participants will continue their sri treatment for 12 weeks. after the 12-week treatment period, participants who received i-cbt or medication management alone and who remain symptomatic will be given cbt as will participants who are asymptomatic but relapse within 6 months after treatment. assessments will be conducted at weeks 0, 4, 8, and 12. follow-up assessments will be conducted at 3 and 6 months post-treatment.

Eligibility criteria:
inclusion criteria: * dsm-iv diagnosis of obsessive compulsive disorder * cybocs total score greater than 16 exclusion criteria: * other primary or co-primary psychiatric disorder * pervasive developmental disorder or disorders, including asperger's syndrome * thought disorder * prior failed trial of cognitive-behavioral therapy * has pediatric autoimmune neuropsychiatric disorders associated with streptococcus (pandas) or maintenance antibiotic for obsessive-compulsive disorder * mental retardation * pregnancy

Keywords: child adolescent
capsaicin nanoparticle in patient with painful diabetic neuropathy

Conditions: Painful Diabetic Neuropathy

Summary: the objectives of this study are to determine efficacy and safety of 0.75% topical capsaicin nanoparticle preparation versus placebo in patient with painful diabetic neuropathy.

painful diabetic neuropathy is the most common cause of neuropathic pain. 0.075% topical capsaicin has been used to treat the pain. because of high concentration, conventional capsaicin topical preparation causing burning sensation and required several time of applications per day. the nanoparticle of capsaicin topical preparation was developed with expectation of remaining efficacy, minimizing burning sensation and improving convenience of use.

Eligibility criteria:
inclusion criteria: * history of type 2 diabetes mellitus * peripheral neuropathy * stabilized on pain medication for at least one month * no previous invasive intervention for pain relief exclusion criteria: * local wound or any skin abnormality in the applicable area * allergic to capsaicin * refuse to participate or give consent * has other significant disease or receive medication that may worsen neuropathy

Keywords: painful diabetic neuropathy capsaicin nanoparticle quantitative sensory testing
bay1830839: first in man, single dose escalation, safety & tolerability and pharmacokinetics

Conditions: Arthritis, Rheumatoid

Summary: the primary objectives of this study are to investigate * the safety and tolerability of increasing single oral doses of bay 1830839 versus placebo under fasted conditions * the pharmacokinetics after single ascending oral doses of bay 1830839 under fasted conditions


Eligibility criteria:
inclusion criteria: * body mass index (bmi) : ≥18.5 and ≤30 kg/m\*2 exclusion criteria: * relevant diseases within the last 4 weeks prior to the first study drug administration * febrile illness within 4 weeks before the first study drug administration * known hypersensitivity to the study drugs or components of the preparations * clinically relevant findings in the physical examination
prehospital kcentra for hemorrhagic shock

Conditions: Trauma Injury

Summary: this is a pilot trial being performed to evaluate the feasibility, to include the ability of ems to identify patients in shock and the ability to package, store, and administer kcentra in the field.

prospective randomized trials have shown that 4-factor prothrombin complex concentrate (4fpccs) result in more rapid correction of coagulopathy and greater likelihood of achieving hemostasis in patients receiving vitamin k antagonists who require emergent operations or who are bleeding. 4fpccs have not been studied in the pre-hospital setting as a primary resuscitative adjunct. the investigators believe the effects of kcentra to prevent or treat coagulopathy early after injury combined with its ability to treat the endotheliopathy of trauma and prevent organ failure will results in improved outcomes in severely injured trauma patients with hemorrhagic shock. the investigators have chosen to study a population of trauma patients in severe hemorrhagic shock (sbp \< 70mmhg) because this population is at greatest risk for developing acute coagulopathy of trauma and has the greatest potential to benefit from the proposed therapy.

Eligibility criteria:
inclusion criteria: 1. trauma patients age 18 years or greater, or weight \> 50 kg if age unknown 2. systolic blood pressure \< 70 mmhg 3. suspicion of hemorrhagic shock based on mechanism of injury 4. ems transport to a participating trauma center exclusion criteria: 1. age less than 18 2. unknown time of injury 3. out-of-hospital cardiopulmonary resuscitation 4. known history of thromboembolic disorders or stroke or suspicion by ems of a recent stroke 5. known oral anti-coagulant use to include warfarin and novel anti-coagulants 6. severe hypothermia (\<28°c) 7. drowning or asphyxia due to hanging 8. burns more than 20% total body surface area 9. evidence of devastating blunt traumatic brain injury to include fixed and dilated pupils, asymmetric pupils and extrusion of brain matter 10. isolated blunt or penetrating head injury 11. isolated spinal cord injury 12. ground level (same level) falls 13. inability to obtain intravenous access 14. inability to administer randomized therapy within 4 hours of ambulance notification 15. known transfers and inter-facility transfers 16. known do not resuscitate (dnr) prior to randomization 17. known or suspected pregnancy 18. known prisoners 19. patients who have activated the "opt-out" process

Keywords: shock, hemorrhagic trauma mortality wounds and injuries hemorrhage
clariance erys registry

Conditions: Spine Degeneration; Spine Spondylosis Thoracic; Spinal Deformity; Spinal Tumor; Spinal Fracture

Summary: international, prospective, single arm, multicenter and observational post-market clinical follow-up (pmcf). the overall objective of this study is to collect preoperative, intraoperative and postoperative (at 9 weeks, 6 months, 1 year and 2 years) data on the clinical complications and functional outcomes of the study devices to demonstrate safety and performance in a real-world setting. the primary objective is to demonstrate that the use of the study devices is safe. the secondary objective is to demonstrate that the use of the study devices decreases the pain, and improves the quality of life and the daily activities of the subjects.


Eligibility criteria:
inclusion criteria: * considered as adult in the respective geography (18 years old or older for france and 21 years old or older for united-states). * indicated for treatment with one or more commercially available sponsor spine device included into the study. * for france only, affiliated with or beneficiary of a social security scheme. exclusion criteria: * subjects who are not able to comply with the study procedures based on the judgment of the investigator (e.g., inability to comprehend study related questions, inability to keep scheduled assessment times). * subjects who are considered as vulnerable: minor, pregnant woman or people under legal protection (guardianship or curatorship). * contraindicated for spine surgery utilizing a commercially available sponsor spine device.
nadroparin pharmacokinetics in different stages of covid-19

Conditions: Thrombosis; Nadroparin; COVID-19; Mechanical Ventilation; Anticoagulants and Bleeding Disorders

Summary: objective: the risk of thrombotic complications in critical covid-19 patients remains extremely high, and multicenter trials failed to prove the survival benefit of escalated doses of low molecular weight heparins (lmwh) in this group. the aim of this study was to develop a pharmacokinetic model of lmwh (nadroparin calcium) according to different stages of covid-19 severity. design: the investigators performed a prospective observational study. patients: blood samples were obtained from 43 covid-19 patients that received nadroparin and were treated with conventional oxygen therapy, mechanical ventilation, and extracorporeal membrane oxygenation. setting: the investigators recorded clinical, biochemical, and hemodynamic variables during 72 hours of treatment. the analyzed data comprised 782 serum nadroparin concentrations and 219 anti-factor xa levels. the investigators conducted population nonlinear mixed-effects modeling (nonmem) and performed monte carlo simulations of the probability of target attainment (pta) for reaching 0.2-0.5 iu/ml anti-xa levels in study groups. interventions: none. measurements and main results: the investigators successfully developed a one-compartment model to describe the population pharmacokinetics of nadroparin in different stages of covid-19. conclusions: different nadroparin dosing is required for patients undergoing mechanical ventilation and ecmo to achieve the same targets as those for non-critically ill patients.


Eligibility criteria:
inclusion criteria: * patients treated in the department of anesthesiology and intensive care and the department of infectious diseases of a tertiary academic hospital with confirmed sars-cov-2 infection with a real-time reverse transcription polymerase chain reaction (rt-pcr) or an antigen test. exclusion criteria: * coagulation disorders at the start of the therapy.
paravertebral versus caudal block in pediatric pcnl

Conditions: Kidney Stones; Percutaneous Nephrolithotomy

Summary: to compare the efficacy of ultrasound guided thoracic paravertebral block versus ultrasound guided caudal epidural block in pediatric patients undergoing percutaneous nephrolithotomy

percutaneous nephrolithotomy (pcnl) is a commonly performed surgical procedure for complex upper renal tract calculi. although the skin incision for pcnl appears small, the intensity of intraoperative and postoperative pain is significant owing to soft tissue injury. paravertebral block is the technique of injecting local anesthetics in a space immediately lateral to where the spinal nerves emerge from the intervertebral foramina. this technique is used increasingly for intra-operative and post-operative. caudal epidural block involves placing a needle through the sacral hiatus to deliver medications into the epidural space. this approach is used widely used for surgical anesthesia and analgesia in pediatric patients. this work aims to compare the efficacy of ultrasound guided thoracic paravertebral block versus ultrasound guided caudal epidural block in pediatric patients undergoing percutaneous nephrolithotomy

Eligibility criteria:
inclusion criteria: * patients undergoing percutaneous nephrolithotomy exclusion criteria: * coagulation disorders * infection at the site of injection * allergy to the local anesthetics used * spinal cord abnormalities or neurological deficits

Keywords: paravertebral block caudal block percutaneous nephrolithotomy pediatric
study of recombinant human thrombin for bleeding during autologous skin grafting

Conditions: Surgical Hemostasis

Summary: the purpose of this study is to evaluate whether rthrombin is safe when used for controlling bleeding during skin graft surgery.

this is a phase 2 multiple site, single-arm, open-label study designed to evaluate the safety of rthrombin in subjects of age 2 to 75 years who are receiving a partial- or full-thickness autologous sheet or mesh grafts following burn or traumatic skin injury. after establishing eligibility, study participants will be treated with topical spray rthrombin at the skin graft recipient site during autologous skin graft surgery. there will be a 1-month follow-up period after the surgery.

Eligibility criteria:
inclusion criteria: * autologous skin grafting with sheet or mesh grafts following burn or traumatic skin injury exclusion criteria: * known antibodies or hypersensitivity to thrombin or other coagulation factors

Keywords: hemostasis grafting, skin hemostatics phase 2
evaluation of the strip periscreen for the fast diagnosis of the spontaneous infection of the liquid of ascites during the cirrhosis

Conditions: Cirrhosis; Liquid of Ascites; Infection

Summary: the forecast of the spontaneous infection of the liquid of ascites (isla) at the cirrhotic patient is still burdened by a heavy mortality. the fast diagnosis of the isla is thus an essential stake to improve the forecast. investigators would so like to estimate the interest of the strip periscreen for the fast diagnosis of the isla at cirrhotic patients . investigators plan to include 670 patients, what would allow to make out a will at least on ascites 2000 on about twenty centers for duration estimated of 12 months.


Eligibility criteria:
inclusion criteria: * male or female over 18 years * presence of ascites due to cirrhosis * hospitalization for a complication of cirrhosis (ascites first decompensation, gastrointestinal bleeding, encephalopathy, etc ...). or * hospitalization to perform a paracentesis evacuated outpatient * patients on long-term antibiotic primary or secondary prophylaxis the spontaneous bacterial peritonitis and with clinical and/or biological signs that suggest spontaneous infection of ascite. exclusion criteria: * patients with ascites urgently admitted to hospital for suspected infection receiving antibiotics for more than 12 hours. * chylous ascites, * hemorrhagic ascites * biliary ascites (straw) * ascites heterogeneous appearance * ascites not related to portal hypertension (peritoneal carcinomatosis, pancreatic ascites, tuberculosis, etc ...) * patient receiving imipenem iv. * patients on long-term antibiotic primary or secondary prophylaxis the spontaneous bacterial peritonitis without clinical and/or biological signs that suggest spontaneous infection of ascite.